ArticleUrology case reports2026
Tumor-informed ctDNA surveillance after radical nephrectomy and level IV IVC thrombectomy for clear cell renal cell carcinoma: Early detection of molecular residual disease.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma with level IV inferior vena cava tumor thrombus is rare and associated with high recurrence risk despite complete resection. We report an 80-year-old man who underwent radical nephrectomy and inferior vena cava thrombectomy with initial negative postoperative imaging. One year later, imaging findings were equivocal, but tumor-informed circulating tumor DNA was detectable, prompting early surgical resection of recurrent disease. Postoperatively, circulating tumor DNA became undetectable. This case highlights the potential role of tumor-informed circulating tumor DNA surveillance in detecting molecular residual disease and guiding management in high-risk renal cell carcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.